References
1. Diamandis EP, Christopoulos TK. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem . 1991;37(5):625-636.
2. Odhaib SA, Mansour AA, Haddad NS. How Biotin Induces Misleading Results in Thyroid Bioassays: Case Series. Cureus . Published online May 23, 2019. doi:10.7759/cureus.4727
3. Evans N, Yates J, Tobin J, McGill J, Huynh T. Immunoassay interference secondary to therapeutic high-dose biotin: A paediatric case report: Biotin interference and thyroid function tests. J Paediatr Child Health . 2018;54(5):572-575. doi:10.1111/jpc.13857
4. Sturgeon CM, Viljoen A. Analytical error and interference in immunoassay: minimizing risk. Ann Clin Biochem . 2011;48(Pt 5):418-432. doi:10.1258/acb.2011.011073
5. Al-Salameh A, Becquemont L, Brailly-Tabard S, Aubourg P, Chanson P. A Somewhat Bizarre Case of Graves Disease Due to Vitamin Treatment.J Endocr Soc . 2017;1(5):431-435. doi:10.1210/js.2017-00054
6. Paketçi A, Köse E, Gürsoy Çalan Ö, et al. Serum Level of Biotin Rather than the Daily Dosage Is the Main Determinant of Interference on Thyroid Function Assays. Horm Res Paediatr . 2019;92(2):92-98. doi:10.1159/000502740
7. Grimsey P, Frey N, Bendig G, et al. Population pharmacokinetics of exogenous biotin and the relationship between biotin serum levels and in vitro immunoassay interference. Int J Pharmacokinet . 2017;2(4):247-256. doi:10.4155/ipk-2017-0013
8. Kummer S, Hermsen D, Distelmaier F. Biotin Treatment Mimicking Graves’ Disease. N Engl J Med . 2016;375(7):704-706. doi:10.1056/NEJMc1602096
9. Sharma A, Baumann NA, Shah P. Biotin-Induced Biochemical Graves Disease: A Teachable Moment. JAMA Intern Med . 2017;177(4):571-572. doi:10.1001/jamainternmed.2016.9295
10. Kwok JS-S, Chan IH-S, Chan MH-M. Biotin interference on TSH and free thyroid hormone measurement. Pathology (Phila) . 2012;44(3):278-280. doi:10.1097/PAT.0b013e3283514002
11. Bowen R, Benavides R, Colón-Franco JM, et al. Best practices in mitigating the risk of biotin interference with laboratory testing.Clin Biochem . 2019;74:1-11. doi:10.1016/j.clinbiochem.2019.08.012
12. Favresse J, Burlacu M-C, Maiter D, Gruson D. Interferences With Thyroid Function Immunoassays: Clinical Implications and Detection Algorithm. Endocr Rev . 2018;39(5):830-850. doi:10.1210/er.2018-00119
13. Piketty M-L, Prie D, Sedel F, et al. High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference. Clin Chem Lab Med CCLM . 2017;55(6):817-825. doi:10.1515/cclm-2016-1183
14. Laji K. Abnormal serum free thyroid hormone levels due to heparin administration. QJM . 2001;94(9):471-473. doi:10.1093/qjmed/94.9.471
15. Burch HB. Drug Effects on the Thyroid. Ingelfinger JR, ed. N Engl J Med . 2019;381(8):749-761. doi:10.1056/NEJMra1901214
16. Jaume JC, Mendel CM, Frost PH, Greenspan FS, Laughton CW. Extremely Low Doses of Heparin Release Lipase Activity into the Plasma and Can Thereby Cause Artifactual Elevations in the Serum-Free Thyroxine Concentration as Measured by Equilibrium Dialysis. Thyroid . 1996;6(2):79-83. doi:10.1089/thy.1996.6.79
17. Stevenson HP, Archbold GP, Johnston P, Young IS, Sheridan B. Misleading serum free thyroxine results during low molecular weight heparin treatment. Clin Chem . 1998;44(5):1002-1007.
18. Koulouri O, Moran C, Halsall D, Chatterjee K, Gurnell M. Pitfalls in the measurement and interpretation of thyroid function tests. Best Pract Res Clin Endocrinol Metab . 2013;27(6):745-762. doi:10.1016/j.beem.2013.10.003
19. Mendel CM, Frost PH, Cavalieri RR. Effect of free fatty acids on the concentration of free thyroxine in human serum: the role of albumin.J Clin Endocrinol Metab . 1986;63(6):1394-1399. doi:10.1210/jcem-63-6-1394
20. Stockigt JR, Lim C-F. Medications that distort in vitro tests of thyroid function, with particular reference to estimates of serum free thyroxine. Best Pract Res Clin Endocrinol Metab . 2009;23(6):753-767. doi:10.1016/j.beem.2009.06.004
21. Braverman LE, Cooper D. Werner & Ingbar’s The Thyroid: A Fundamental and Clinical Text . Lippincott Williams & Wilkins; 2012.
22. Schussler GC. The Thyroxine-Binding Proteins. Thyroid . 2000;10(2):141-149. doi:10.1089/thy.2000.10.141
23. Knopp RH, Bergelin RO, Wahl PW, Walden CE, Chapman MB. Clinical chemistry alterations in pregnancy and oral contraceptive use.Obstet Gynecol . 1985;66(5):682-690.
24. Steingold KA, Matt DW, DeZiegler D, Sealey JE, Fratkin M, Reznikov S. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure.J Clin Endocrinol Metab . 1991;73(2):275-280. doi:10.1210/jcem-73-2-275
25. Kuhl H, Jung-Hoffmann C, Weber J, Boehm BO. The effect of a biphasic desogestrel-containing oral contraceptive on carbohydrate metabolism and various hormonal parameters. Contraception . 1993;47(1):55-68. doi:10.1016/0010-7824(93)90109-k
26. Geola FL, Frumar AM, Tataryn IV, et al. Biological effects of various doses of conjugated equine estrogens in postmenopausal women.J Clin Endocrinol Metab . 1980;51(3):620-625. doi:10.1210/jcem-51-3-620
27. Ben-Rafael Z, Struass JF, Arendash-Durand B, Mastroianni L, Flickinger GL. Changes in thyroid function tests and sex hormone binding globulin associated with treatment by gonadotropin. Fertil Steril . 1987;48(2):318-320. doi:10.1016/s0015-0282(16)59363-7
28. Wiegratz I, Kutschera E, Lee JH, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins.Contraception . 2003;67(1):25-32. doi:10.1016/S0010-7824(02)00436-5
29. Bisschop PH, Toorians AW, Endert E, Wiersinga WM, Gooren LJ, Fliers E. The effects of sex-steroid administration on the pituitary–thyroid axis in transsexuals. Eur J Endocrinol . 2006;155(1):11-16. doi:10.1530/eje.1.02192
30. Ain KB, Mori Y, Refetoff S. Reduced Clearance Rate of Thyroxine-Binding Globulin (TBG) with Increased Sialylation: A Mechanism for Estrogen-Induced Elevation of Serum TBG Concentration*. J Clin Endocrinol Metab . 1987;65(4):689-696. doi:10.1210/jcem-65-4-689
31. Glinoer D, Gershengorn MC, Dubois A, Robbins J. Stimulation of thyroxine-binding globulin synthesis by isolated rhesus monkey hepatocytes after in vivo beta-estradiol administration.Endocrinology . 1977;100(3):807-813. doi:10.1210/endo-100-3-807
32. Glinoer D, McGuire RA, Gershengorn MC, Robbins J, Berman M. Effects of estrogen on thyroxine-binding globulin metabolism in rhesus monkeys.Endocrinology . 1977;100(1):9-17. doi:10.1210/endo-100-1-9
33. Gordon D, Beastall GH, Thomson JA. The effect of tamoxifen therapy on thyroid function tests. (7):4.
34. Kostoglou-Athanassiou I, Ntalles K, Markopoulos C, Athanassiou P, Gogas J, Proukakis C. Thyroid function in postmenopausal women with breast cancer on tamoxifen. Eur J Gynaecol Oncol . 1998;19(2):150-154.
35. Mamby CC, Love RR, Lee KE. Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer.J Clin Oncol . 1995;13(4):854-857. doi:10.1200/JCO.1995.13.4.854
36. Anker GB, Lønning PE, Aakvaag A, Lien EA. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen.Scand J Clin Lab Invest . 1998;58(2):103-107. doi:10.1080/00365519850186670
37. Duntas LH, Mantzou E, Koutras DA. Lack of Substantial Effects of Raloxifene on Thyroxine-Binding Globulin in Postmenopausal Women: Dependency on Thyroid Status. Thyroid . 2001;11(8):779-782. doi:10.1089/10507250152484637
38. Hsu SH-J, Cheng W-C, Jang M-W, Tsai K-S. Effects of Long-Term Use of Raloxifene, a Selective Estrogen Receptor Modulator, on Thyroid Function Test Profiles. Clin Chem . 2001;47(10):1865-1867. doi:10.1093/clinchem/47.10.1865
39. Ceresini G, Morganti S, Rebecchi I, et al. A one-year follow-up on the effects of raloxifene on thyroid function in postmenopausal women.Menopause N Y N . 2004;11(2):176-179. doi:10.1097/01.gme.0000094169.64352.3b
40. Marqusee E, Braverman LE, Lawrence JE, Carroll JS, Seely EW. The effect of droloxifene and estrogen on thyroid function in postmenopausal women. J Clin Endocrinol Metab . 2000;85(11):4407-4410. doi:10.1210/jcem.85.11.6975
41. Azizi F. Thyroxine Transport and Metabolism in Methadone and Heroin Addicts. Ann Intern Med . 1974;80(2):194. doi:10.7326/0003-4819-80-2-194
42. English TN, Ruxton D, Eastman CJ. Abnormalities in thyroid function associated with chronic therapy with methadone. Clin Chem . 1988;34(11):2202-2204.
43. Bastomsky CH, Dent RR, Tolis G. Elevated serum concentrations of thyroxine-binding globulin and caeruloplasmin in methadone-maintained patients. Clin Biochem . 1977;10(3):124-126. doi:10.1016/s0009-9120(77)91682-4
44. Webster JB, Coupal JJ, Cushman P. Increased serum thyroxine levels in euthyroid narcotic addicts. J Clin Endocrinol Metab . 1973;37(6):928-934. doi:10.1210/jcem-37-6-928
45. Gozashti MH, Mohammadzadeh E, Divsalar K, Shokoohi M. The effect of opium addiction on thyroid function tests. J Diabetes Metab Disord . 2014;13(1):5. doi:10.1186/2251-6581-13-5
46. Farhad Shahsavar, Koroush Ghanadi, Jafarzadeh M, Mehrzad Jafarzadeh, Bahram Nasiri, Shahab Forutani. Opium addiction decreases T3 uptake amount. Life Sci J . 2013;10(Special Issue 5 (Supplement 1005s)):608-610. doi:10.7537/marslsj1005s13.105
47. Yan Z, Yan H, Ou H. Human thyroxine binding globulin (TBG) promoter directs efficient and sustaining transgene expression in liver-specific pattern. Gene . 2012;506(2):289-294. doi:10.1016/j.gene.2012.07.009
48. Schussler GC, Stimmel B, Korn F. Increased serum thyroid hormone binding in narcotic addicts is due to liver disease. Am J Drug Alcohol Abuse . 1980;7(3-4):379-387. doi:10.3109/00952998008993434
49. Beex L, Ross A, Smals A, Kloppenborg P. 5-fluorouracil-induced increase of total serum thyroxine and triiodothyronine. Cancer Treat Rep . 1977;61(7):1291-1295.
50. Mitotane increases the blood levels of hormone-binding proteins. - PubMed - NCBI. Accessed April 22, 2020. https://www.ncbi.nlm.nih.gov/pubmed/1903011
51. Marshall JS, Tompkin LS. Effect of o,p’-DDD and Similar Compounds on Thyroxine Binding Globulin. J Clin Endocrinol Metab . 1968;28(3):386-392. doi:10.1210/jcem-28-3-386
52. Daffara F, De Francia S, Giuseppe Reimondo, Zaggia B,. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer . 2008;15((4)):1043-1053. doi:10.1677/erc-08-0103
53. Russo M, Scollo C, Pellegriti G, et al. Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism.Clin Endocrinol (Oxf) . 2016;84(4):614-619. doi:10.1111/cen.12868
54. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest . 2006;116(10):2571-2579. doi:10.1172/JCI29812
55. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators.Lancet Lond Engl . 1984;2(8403):600-604.
56. McKerron CG, Scott RL, Asper SP, Levy RI. Effects of clofibrate (Atromid S) on the thyroxine-binding capacity of thyroxine-binding globulin and free thyroxine. J Clin Endocrinol Metab . 1969;29(7):957-961. doi:10.1210/jcem-29-7-957
57. Barbosa J, Oliner L. Effect of clofibrate on serum thyroxine transport and free thyroxine levels. Metabolism . 1969;18(2):141-147. doi:10.1016/0026-0495(69)90108-5
58. Deyssig R, Weissel M. Ingestion of androgenic-anabolic steroids induces mild thyroidal impairment in male body builders. J Clin Endocrinol Metab . 1993;76(4):1069-1071. doi:10.1210/jcem.76.4.8473383
59. Malarkey WB, Strauss RH, Leizman DJ, Liggett M, Demers LM. Endocrine effects in female weight lifters who self-administer testosterone and anabolic steroids. Am J Obstet Gynecol . 1991;165(5 Pt 1):1385-1390. doi:10.1016/0002-9378(91)90374-z
60. Kley HK, Herrmann J, Morgner KD, Krüskemper HL. Effects of testosterone oenanthate on plasma concentrations of thyroxine, cortisol, testosterone and hormone binding proteins in patients with hypogonadism.Horm Metab Res Horm Stoffwechselforschung Horm Metab . 1973;5(4):271-274. doi:10.1055/s-0028-1093945
61. Small M, Beastall GH, Semple CG, Cowan RA, Forbes CD. Alteration of hormone levels in normal males given the anabolic steroid stanozolol.Clin Endocrinol (Oxf) . 1984;21(1):49-55. doi:10.1111/j.1365-2265.1984.tb00135.x
62. Graham RL, Gambrell RD. Changes in thyroid function tests during danazol therapy. Obstet Gynecol . 1980;55(3):395-397. doi:10.1097/00006250-198003000-00028
63. Arafah BM. Decreased levothyroxine requirement in women with hypothyroidism during androgen therapy for breast cancer. Ann Intern Med . 1994;121(4):247-251. doi:10.7326/0003-4819-121-4-199408150-00002
64. Becker U, Gluud C, Bennett P, The Copenhagen Study Group for Liver Diseases. The effect of oral testosterone on serum TBG levels in alcoholic cirrhotic men. Liver . 2008;8(4):219-224. doi:10.1111/j.1600-0676.1988.tb00996.x
65. Braverman LE, Ingbar SH. Effects of Norethandrolone on the Transport in Serum and Peripheral Turnover of Thyroxine. J Clin Endocrinol Metab . 1967;27(3):389-396. doi:10.1210/jcem-27-3-389
66. Tahboub R, Arafah BM. Sex steroids and the thyroid. Best Pract Res Clin Endocrinol Metab . 2009;23(6):769-780. doi:10.1016/j.beem.2009.06.005
67. Surks MI, Sievert R. Drugs and Thyroid Function. Wood AJJ, ed.N Engl J Med . 1995;333(25):1688-1694. doi:10.1056/NEJM199512213332507
68. Emerson CH, Seiler CM, Alex S, Fang SL, Mori Y, DeVito WJ. Gene expression and serum thyroxine-binding globulin are regulated by adrenal status and corticosterone in the rat. Endocrinology . 1993;133(3):1192-1196. doi:10.1210/endo.133.3.8365361
69. Oppenheimer JH, Werner SC, Martinez M. Effect of Prednisone on Thyroxine-Binding Proteins. J Clin Endocrinol Metab . 1966;26(7):715-721. doi:10.1210/jcem-26-7-715
70. Bartalena L, Martino E, Antonelli A, Pacchiarotti A, Robbins J, Pinchera A. Effect of the antileukemic agent L-asparaginase on thyroxine-binding globulin and albumin synthesis in cultured human hepatoma (HEP G2) cells. Endocrinology . 1986;119(3):1185-1188. doi:10.1210/endo-119-3-1185
71. Ferster A, Glinoér D, Vliet GV, Otten J. Thyroid Function During L-Asparaginase Therapy in Children with Acute Lymphoblastic Leukemia: Difference Between Induction and Late Intensification. J Pediatr Hematol Oncol . 1992;14(3):192–196.
72. Heidemann PH, Stubbe P, Beck W. Transient secondary hypothyroidism and thyroxine binding globulin deficiency in leukemic children during polychemotherapy: An effect of L-asparaginase. Eur J Pediatr . 1981;136(3):291-295. doi:10.1007/BF00442997
73. Garnick MB, Larsen PR. Acute Deficiency of Thyroxine-Binding Globulin during L-Asparaginase Therapy. N Engl J Med . 1979;301(5):252-253. doi:10.1056/NEJM197908023010506
74. Fadilah SA, Faridah I, Cheong SK. Transient hyperthyroidism following L-asparaginase therapy for acute lymphoblastic leukemia.Med J Malaysia . 2000;55(4):513-515.
75. Shakir KM, Kroll S, Aprill BS, Drake AJ, Eisold JF. Nicotinic acid decreases serum thyroid hormone levels while maintaining a euthyroid state. Mayo Clin Proc . 1995;70(6):556-558. doi:10.4065/70.6.556
76. O’Brien T, Silverberg JD, Nguyen TT. Nicotinic acid-induced toxicity associated with cytopenia and decreased levels of thyroxine-binding globulin. Mayo Clin Proc . 1992;67(5):465-468. doi:10.1016/s0025-6196(12)60393-0
77. Drinka PJ. Alterations in thyroid and hepatic function tests associated with preparations of sustained-release niacin. Mayo Clin Proc . 1992;67(12):1206. doi:10.1016/s0025-6196(12)61154-9
78. Cashin-Hemphill L, Spencer CA, Nicoloff JT, et al. Alterations in serum thyroid hormonal indices with colestipol-niacin therapy. Ann Intern Med . 1987;107(3):324-329. doi:10.7326/0003-4819-107-2-324
79. Wang R, Nelson JC, Wilcox RB. Salsalate and Salicylate Binding to and their Displacement of Thyroxine from Thyroxine-Binding Globulin, Transthyretin, and Albumin. Thyroid . 1999;9(4):359-364. doi:10.1089/thy.1999.9.359
80. Larsen PR. Salicylate-induced increases in free triiodothyronine in human serum. Evidence of inhibition of triiodothyronine binding to thyroxine-binding globulin and thyroxine-binding prealbumin. J Clin Invest . 1972;51(5):1125-1134. doi:10.1172/JCI106905
81. Faber J, Waetjen I, Siersbaek-Nielsen K. Free thyroxine measured in undiluted serum by dialysis and ultrafiltration: effects of non-thyroidal illness, and an acute load of salicylate or heparin.Clin Chim Acta Int J Clin Chem . 1993;223(1-2):159-167. doi:10.1016/0009-8981(93)90072-c
82. McConnell RJ. Abnormal thyroid function test results in patients taking salsalate. JAMA . 1992;267(9):1242-1243.
83. Samuels MH, Pillote K, Asher D, Nelson JC. Variable Effects of Nonsteroidal Antiinflammatory Agents on Thyroid Test Results. J Clin Endocrinol Metab . 2003;88(12):5710-5716. doi:10.1210/jc.2002-021869
84. Stockigt JR, Lim CF, Barlow JW, et al. Interaction of furosemide with serum thyroxine-binding sites: in vivo and in vitro studies and comparison with other inhibitors. J Clin Endocrinol Metab . 1985;60(5):1025-1031. doi:10.1210/jcem-60-5-1025
85. Newnham HH, Hamblin PS, Long F, Lim C-F, Topliss DJ, Stockigt JR. Effect of oral frusemide on diagnostic indices of thyroid function.Clin Endocrinol (Oxf) . 1987;26(4):423-431. doi:10.1111/j.1365-2265.1987.tb00799.x
86. Zhang Y-X, Shen C-H, Lai Q-L, et al. Effects of antiepileptic drug on thyroid hormones in patients with epilepsy: A meta-analysis.Seizure . 2016;35:72-79. doi:10.1016/j.seizure.2016.01.010
87. Surks MI, DeFesi CR. Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine. A paradox resolved. JAMA . 1996;275(19):1495-1498.
88. Chopra IJ, Van Herle AJ, Teco GN, Nguyen AH. Serum free thyroxine in thyroidal and nonthyroidal illnesses: a comparison of measurements by radioimmunoassay, equilibrium dialysis, and free thyroxine index.J Clin Endocrinol Metab . 1980;51(1):135-143. doi:10.1210/jcem-51-1-135